Shorla Oncology is a pioneering Irish pharmaceutical company dedicated to improving lives through science and innovation. Co-founded by Sharon Cunningham and Orlaith Ryan, Shorla’s mission is to make existing oncology treatments better through formulation innovation. By working closely with key opinion leaders, clinicians and research scientists, the company addresses real-world clinical challenges in areas of unmet need.
Shorla Oncology focuses on paediatric and orphan cancers, where treatment options are limited, inadequate or in shortage. Through rethinking and improving therapies, Shorla delivers accessible, affordable, and lifesaving cancer medicines to vulnerable patient populations. With FDA approved products now available in the United States and operations in Ireland and the US, Shorla’s growing portfolio aims to make a meaningful clinical impact, bringing hope, compassion and effective treatments to patients who need them most.